BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

756 related articles for article (PubMed ID: 31153730)

  • 1. Breast cancer hormone receptor negativity, triple-negative type, mastectomy and not receiving adjuvant radiotherapy were associated with axillary recurrence after sentinel lymph node biopsy.
    Sekine C; Nakano S; Mibu A; Otsuka M; Oinuma T; Takeyama H
    Asian J Surg; 2020 Jan; 43(1):148-153. PubMed ID: 31153730
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of Post Mastectomy Radiation Therapy in Patients Receiving Axillary Lymph Node Dissection After Positive Sentinel Lymph Node Biopsy.
    Stauder MC; Caudle AS; Allen PK; Shaitelman SF; Smith BD; Hoffman KE; Buchholz TA; Chavez-Macgregor M; Hunt KK; Meric-Bernstam F; Woodward WA
    Int J Radiat Oncol Biol Phys; 2016 Nov; 96(3):637-44. PubMed ID: 27681760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Is axillary lymph node dissection necessary after sentinel lymph node biopsy in patients with mastectomy and pathological N1 breast cancer?
    Fu Y; Chung D; Cao MA; Apple S; Chang H
    Ann Surg Oncol; 2014 Dec; 21(13):4109-23. PubMed ID: 25081336
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sentinel lymph node biopsy in breast cancer patients after neoadjuvant chemotherapy.
    Reitsamer R; Peintinger F; Rettenbacher L; Prokop E
    J Surg Oncol; 2003 Oct; 84(2):63-7. PubMed ID: 14502778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Management of the Axilla in T1-2 Breast Cancer Patients with Macrometastatic Sentinel Node Involvement Who Underwent Breast-Conserving Therapy.
    Kuru B; Yuruker S; Sullu Y; Gursel B; Ozen N
    J Invest Surg; 2019 Jan; 32(1):48-54. PubMed ID: 28945489
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nodal Recurrence in Patients With Node-Positive Breast Cancer Treated With Sentinel Node Biopsy Alone After Neoadjuvant Chemotherapy-A Rare Event.
    Barrio AV; Montagna G; Mamtani A; Sevilimedu V; Edelweiss M; Capko D; Cody HS; El-Tamer M; Gemignani ML; Heerdt A; Kirstein L; Moo TA; Pilewskie M; Plitas G; Sacchini V; Sclafani L; Tadros A; Van Zee KJ; Morrow M
    JAMA Oncol; 2021 Dec; 7(12):1851-1855. PubMed ID: 34617979
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oncological Safety of Skipping Axillary Lymph Node Dissection in Patients with Clinical N0, Sentinel Node-Positive Breast Cancer Undergoing Total Mastectomy.
    Chun JW; Kang E; Kim HK; Lee HB; Moon HG; Lee JW; Han W
    Ann Surg Oncol; 2024 May; 31(5):3168-3176. PubMed ID: 38368292
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sentinel-lymph-node resection compared with conventional axillary-lymph-node dissection in clinically node-negative patients with breast cancer: overall survival findings from the NSABP B-32 randomised phase 3 trial.
    Krag DN; Anderson SJ; Julian TB; Brown AM; Harlow SP; Costantino JP; Ashikaga T; Weaver DL; Mamounas EP; Jalovec LM; Frazier TG; Noyes RD; Robidoux A; Scarth HM; Wolmark N
    Lancet Oncol; 2010 Oct; 11(10):927-33. PubMed ID: 20863759
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Locoregional Recurrence After Sentinel Lymph Node Dissection With or Without Axillary Dissection in Patients With Sentinel Lymph Node Metastases: Long-term Follow-up From the American College of Surgeons Oncology Group (Alliance) ACOSOG Z0011 Randomized Trial.
    Giuliano AE; Ballman K; McCall L; Beitsch P; Whitworth PW; Blumencranz P; Leitch AM; Saha S; Morrow M; Hunt KK
    Ann Surg; 2016 Sep; 264(3):413-20. PubMed ID: 27513155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Age and Receptor Status Do Not Indicate the Need for Axillary Dissection in Patients with Sentinel Lymph Node Metastases.
    Mamtani A; Patil S; Van Zee KJ; Cody HS; Pilewskie M; Barrio AV; Heerdt AS; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3481-3486. PubMed ID: 27169771
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Microscopic Extracapsular Extension in Sentinel Lymph Nodes Does Not Mandate Axillary Dissection in Z0011-Eligible Patients.
    Barrio AV; Downs-Canner S; Edelweiss M; Van Zee KJ; Cody HS; Gemignani ML; Pilewskie ML; Plitas G; El-Tamer M; Kirstein L; Capko D; Patil S; Morrow M
    Ann Surg Oncol; 2020 May; 27(5):1617-1624. PubMed ID: 31820212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current trends of sentinel lymph node biopsy for breast cancer--a surgeon's perspective.
    Takei H; Kurosumi M; Yoshida T; Ninomiya J; Hagiwara Y; Kamimura M; Hayashi Y; Tozuka K; Suemasu K; Inoue K; Tabei T
    Breast Cancer; 2007; 14(4):362-70. PubMed ID: 17986801
    [TBL] [Abstract][Full Text] [Related]  

  • 13. How Often Does Neoadjuvant Chemotherapy Avoid Axillary Dissection in Patients With Histologically Confirmed Nodal Metastases? Results of a Prospective Study.
    Mamtani A; Barrio AV; King TA; Van Zee KJ; Plitas G; Pilewskie M; El-Tamer M; Gemignani ML; Heerdt AS; Sclafani LM; Sacchini V; Cody HS; Patil S; Morrow M
    Ann Surg Oncol; 2016 Oct; 23(11):3467-3474. PubMed ID: 27160528
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sentinel lymph node surgery after neoadjuvant chemotherapy in patients with node-positive breast cancer: the ACOSOG Z1071 (Alliance) clinical trial.
    Boughey JC; Suman VJ; Mittendorf EA; Ahrendt GM; Wilke LG; Taback B; Leitch AM; Kuerer HM; Bowling M; Flippo-Morton TS; Byrd DR; Ollila DW; Julian TB; McLaughlin SA; McCall L; Symmans WF; Le-Petross HT; Haffty BG; Buchholz TA; Nelson H; Hunt KK;
    JAMA; 2013 Oct; 310(14):1455-61. PubMed ID: 24101169
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel lymph node biopsy following previous axillary surgery in recurrent breast cancer.
    Sávolt Á; Cserni G; Lázár G; Maráz R; Kelemen P; Kovács E; Győrffy B; Udvarhelyi N; Vörös A; Ormándi K; Mátrai Z
    Eur J Surg Oncol; 2019 Oct; 45(10):1835-1838. PubMed ID: 31126680
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcomes of Stage I and II Breast Cancer with Nodal Micrometastases Treated with Mastectomy without Axillary Therapy.
    Lim SZ; Kusumawidjaja G; Mohd Ishak HM; Tan BKT; Tan SY; Hamzah JL; Madhukumar P; Yong WS; Wong CY; Sim Y; Lim GH; Lim SH; Tan SM; Wong FY; Tan VKM
    Breast Cancer Res Treat; 2021 Oct; 189(3):837-843. PubMed ID: 34342766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radiation field design and regional control in sentinel lymph node-positive breast cancer patients with omission of axillary dissection.
    Setton J; Cody H; Tan L; Morrow M; Hudis C; Catalano J; McCormick B; Powell S; Ho A
    Cancer; 2012 Apr; 118(8):1994-2003. PubMed ID: 21882186
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sentinel lymph node biopsy alone without axillary lymph node dissection--follow up of sentinel lymph node negative breast cancer patients.
    Reitsamer R; Peintinger F; Prokop E; Menzel C; Cimpoca W; Rettenbacher L
    Eur J Surg Oncol; 2003 Apr; 29(3):221-3. PubMed ID: 12657230
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omission of axillary lymph node dissection for breast cancer patients with three or more positive sentinel lymph nodes.
    Prathibha S; White M; Kolbow M; Hui JYC; Brauer D; Ankeny J; Jensen EH; LaRocca CJ; Marmor S; Tuttle TM
    Breast Cancer Res Treat; 2024 May; 205(1):127-133. PubMed ID: 38281296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multidisciplinary Management of the Axilla in Patients with cT1-T2 N0 Breast Cancer Undergoing Primary Mastectomy: Results from a Prospective Single-Institution Series.
    Grossmith S; Nguyen A; Hu J; Plichta JK; Nakhlis F; Cutone L; Dominici L; Golshan M; Duggan M; Carter K; Rhei E; Barbie T; Calvillo K; Nimbkar S; Bellon J; Wong J; Punglia R; Barry W; King TA
    Ann Surg Oncol; 2018 Nov; 25(12):3527-3534. PubMed ID: 29868979
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.